The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2- advanced breast cancer (ABC): Preliminary results.
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Biotheyx; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Scorpion Therapeutics; Seagen; Silverback Therapeutics
Speakers' Bureau - Merck; San Antonio Pancreatic Cancer Symposium
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Ambrx (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Arvinas (Inst); Astellas Pharma (Inst); BioNTech (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Ensem (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Olema Oncology (Inst); Ottimo (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Pfizer; Regeneron; Vertex
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Pliant; Whitehawk Therapeutics
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Arcus Biosciences (Inst); Artios (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Circle Pharma (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); Debiopharm Group (Inst); Deciphera (Inst); EvolveImmune Therapeutics (Inst); Exelixis (Inst); Exscientia (Inst); FoRx Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Halda Therapeutics (Inst); Helsinn Therapeutics (Inst); Iambic Therapeutics (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); KLUS Pharma (Inst); Kumquat Biosciences (Inst); Macrogenics (Inst); Mbrace Therapeutics (Inst); MediLink Therapeutics (Inst); Menarini Group (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mitsubishi Tanabe Pharma (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Olema Pharmaceuticals (Inst); Opna Bio (Inst); Pfizer (Inst); Pliant (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Third Arc Bio (Inst); Treeline Biosciences (Inst); VelaVigo Bio (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
William McKean
Consulting or Advisory Role - Recursion Pharmaceuticals
 
Rohit Joshi
Honoraria - Bristol-Myers Squibb; Gilead Sciences; Ipsen; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Roche
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
Speakers' Bureau - Gilead Sciences
Travel, Accommodations, Expenses - Novartis
 
Antonio Giordano
Consulting or Advisory Role - Araris; Arvinas; CancerNet; Guardant Health; Guidepoint Inc; Lilly; Lilly; Lilly; Medscape; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Stop Cancer
Research Funding - Cardiff Oncology (Inst)
Travel, Accommodations, Expenses - Lilly; Pfizer; Totus Medicines
 
Shou-Ching Tang
No Relationships to Disclose
 
Lixian Sun
Employment - Olema Oncology
Stock and Other Ownership Interests - Olema Oncology
 
Morena Shaw
Employment - Olema Oncology
Stock and Other Ownership Interests - Olema Oncology
 
James Lau
Employment - Olema Oncology
Stock and Other Ownership Interests - AstraZeneca; Olema Oncology
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Johnson & Johnson/Janssen; Kura Oncology; Mitsubishi Tanabe Pharma; shivanka Research
Research Funding - Abbvie (Inst); Abdera Thereapeutics (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Syndax (Inst); Systimmune (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)